Eli Lilly to Showcase Innovative Cancer Research Presentations
Eli Lilly and Company (NYSE: LLY) is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting, where it will present groundbreaking preclinical data focused on cancer therapies. This highly anticipated event is set to take place shortly, bringing together leading experts and researchers in the field to discuss advancements in oncology.
One of the highlights of the meeting will include the oral presentation of information on agents that target SMARCA2 (BRM) and various mutations related to KRAS. These presentations reflect Lilly’s ongoing commitment to cancer research and its leadership in developing innovative treatment approaches. The meeting will be hosted in a dynamic setting with a focus on sharing insights and knowledge among specialists.
Collaborative Efforts in Cancer Treatment
Lilly will collaborate with Foghorn Therapeutics to unveil vital preclinical data for LY4050784, a selective inhibitor of SMARCA2. This particular treatment will be showcased in combination with chemotherapy, pembrolizumab, and KRAS inhibitors, providing insights into its efficacy against SMARCA4 mutant cancers in preclinical models.
Adding to the excitement, Lilly will also share data on LY4066434, a pan-KRAS inhibitor specifically designed to offer potency while selectively targeting KRAS over HRAS and NRAS. Both of these advanced therapies are currently progressing through Phase 1 studies, indicating Lilly's dedication to expanding treatment options for patients with challenging cancer diagnoses.
Details on Upcoming Presentations
During the AACR Annual Meeting, Eli Lilly and its collaborators will present the following:
LY4050784 Presentation Highlights
Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors.
Abstract Number: 3779
Date & Time: Monday, April 28, 2:30-4:30 p.m.
Session Title: Continuum of Innovation: Biological Therapeutic Agents
Presenter: Nathan Brooks
LY4066434 Presentation Highlights
Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS.
Abstract Number: 4375
Date & Time: Tuesday, April 29, 9 a.m.-12 p.m.
Session Title: RAS Inhibitors
Presenter: Hong Gao
About Eli Lilly
Eli Lilly is a trailblazer in the pharmaceutical industry, dedicated to transforming scientific innovation into real-world healing solutions. With nearly 150 years of experience, Lilly has impacted the lives of millions globally with its range of medicines. The company is actively engaged in tackling significant health challenges, including redefining diabetes management, addressing obesity, and advancing treatments for Alzheimer's disease and a variety of cancers.
Through their innovative approach to clinical trials, Lilly emphasizes diversity and strives to make their medicines accessible to all. The company continues to push the boundaries of science to ensure a healthier future for more people.
Frequently Asked Questions
What significant data will Eli Lilly present at the AACR meeting?
Eli Lilly will present preclinical data on LY4050784 and LY4066434, focusing on cancer therapies targeting SMARCA2 and KRAS mutations.
Who is collaborating with Lilly on these presentations?
Lilly is collaborating with Foghorn Therapeutics for the presentations on innovative cancer therapies.
When will these presentations take place?
The presentations will occur during the AACR Annual Meeting from April 25–30.
How does Lilly contribute to cancer research?
Lilly invests heavily in research and development, focusing on innovative treatments for various forms of cancer, aimed at improving patient outcomes.
What is Lilly's overall mission?
Lilly's mission is to make life better for people around the world through scientific innovation and accessible healthcare solutions.
